Core Viewpoint - Leshu Health Limited, a multinational health products company focusing on emerging markets like Africa, has successfully listed on the Hong Kong Stock Exchange on November 10, raising a net amount of HKD 22.29 billion through its IPO [1][4]. Group 1: IPO Details - The IPO price was set at HKD 26.2, with a total of 90.88 million shares issued, resulting in a total fundraising amount of HKD 23.81 billion [1]. - The cornerstone investors include BA Capital, Arc Avenue, Arcane Nexus, and several others, collectively subscribing to USD 139 million [2][3]. Group 2: Financial Performance - For the first four months of 2025, the company reported revenue of USD 161.31 million and a profit of USD 31.1 million [10][11]. - Revenue projections for 2022, 2023, and 2024 are USD 319.9 million, USD 411.4 million, and USD 454.4 million respectively, with corresponding profits of USD 18.39 million, USD 64.68 million, and USD 95.11 million [11][12]. Group 3: Business Strategy - The net proceeds from the IPO will primarily be used to expand overall production capacity and upgrade production lines, with additional funds allocated for global business expansion and operational enhancements [4]. - Leshu Health aims to replicate its "localized products + self-built channels" model in emerging markets to compete for leadership in the global health products sector [4][9]. Group 4: Shareholding Structure - Prior to the IPO, the controlling shareholders, Shen Yanchang and Yang Yanjuan, held 66.42% of the company through Century BVI [15][22]. - Post-IPO, their stake decreased to 54.75%, while other shareholders like Luo Jichao and Wang Dajiang hold 5.69% and 1.48% respectively [24].
乐舒适港股上市：市值200亿港元，靠在非洲卖卫生用品年营收4.5亿美元